Monthly Archives: March 2017

Biothera Announces Three Presentations at Upcoming American Association for Cancer Research Annual Meeting

EAGAN, MN — March 27, 2017 — Biothera Pharmaceuticals Inc. announced today that it will present three scientific posters at the American Association for Cancer Research (AACR) Annual Meeting April 1-5 in Washington, D.C. One poster was selected for the late-breaking session that highlights the newest and most exciting research. Poster Presentations: Session Date & Time:  Monday, April 3, 8:00 AM – 12:00 PM Eastern...

Read More


Biothera Pharmaceuticals’ Phase 2 Study of Imprime PGG Combination Therapy in Non-Small Cell Lung Cancer Patients Published in Investigational New Drugs

EAGAN, MN — March 24, 2017 — Biothera Pharmaceuticals, Inc. today announced peer-reviewed publication of results of a randomized Phase 2 clinical study of the Company’s cancer immunotherapy Imprime PGG in combination with Erbitux® (cetuximab) and chemotherapy in metastatic non-small cell lung cancer (NSCLC) patients. The study findings have been published online in the journal Investigational New Drugs. Completed by Biothera in 2013, the study was...

Read More